TY - JOUR
T1 - The prevalence and management of anemia in chronic kidney disease patients
T2 - Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOWCKD)
AU - Ryu, Sang Ryol
AU - Park, Sue K.
AU - Jung, Ji Yong
AU - Kim, Yeong Hoon
AU - Oh, Yun Kyu
AU - Yoo, Tae Hyun
AU - Sung, Suah
N1 - Publisher Copyright:
© 2017 The Korean Academy of Medical Sciences.
PY - 2017
Y1 - 2017
N2 - Anemia is a common and significant complication of chronic kidney disease (CKD). However, its prevalence and current management status has not been studied thoroughly in Korea. We examined the prevalence of anemia, its association with clinical and laboratory factors, and utilization of iron agents and erythropoiesis stimulating agents using the baseline data from the large-scale CKD cohort in Korea. We defined anemia when hemoglobin level was lower than 13.0 g/dL in males and 12.0 g/dL in females, or received by erythropoiesis stimulating agents. Overall prevalence of anemia was 45.0% among 2,198 non-dialysis CKD patients from stage 1 to 5. Diabetic nephropathy (DN) as a cause, CKD stages, body mass index (BMI), smoking, leukocyte count, serum albumin, iron markers, calcium, and phosphorus concentration were identified as independent risk factors for anemia. Considering the current coverage of Korean National Health Insurance System, only 7.9% among applicable patients were managed by intravenous iron agents, and 42.7% were managed by erythropoiesis stimulating agents.
AB - Anemia is a common and significant complication of chronic kidney disease (CKD). However, its prevalence and current management status has not been studied thoroughly in Korea. We examined the prevalence of anemia, its association with clinical and laboratory factors, and utilization of iron agents and erythropoiesis stimulating agents using the baseline data from the large-scale CKD cohort in Korea. We defined anemia when hemoglobin level was lower than 13.0 g/dL in males and 12.0 g/dL in females, or received by erythropoiesis stimulating agents. Overall prevalence of anemia was 45.0% among 2,198 non-dialysis CKD patients from stage 1 to 5. Diabetic nephropathy (DN) as a cause, CKD stages, body mass index (BMI), smoking, leukocyte count, serum albumin, iron markers, calcium, and phosphorus concentration were identified as independent risk factors for anemia. Considering the current coverage of Korean National Health Insurance System, only 7.9% among applicable patients were managed by intravenous iron agents, and 42.7% were managed by erythropoiesis stimulating agents.
UR - http://www.scopus.com/inward/record.url?scp=85011685225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011685225&partnerID=8YFLogxK
U2 - 10.3346/jkms.2017.32.2.249
DO - 10.3346/jkms.2017.32.2.249
M3 - Article
C2 - 28049235
AN - SCOPUS:85011685225
SN - 1011-8934
VL - 32
SP - 249
EP - 256
JO - Journal of Korean medical science
JF - Journal of Korean medical science
IS - 2
ER -
